3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What is the projected burden of the opioid epidemic in fatal overdoses, and interventions such as prescribing reductions, naloxone distribution, and treatment expansion associated with mitigation of the epidemic?

          Findings

          In this decision analytical model of the US population aged 12 years or older, under status quo, an estimated 484 429 individuals were projected to die of fatal opioid overdose over 10 years. A combination of reducing opioid prescribing, increasing naloxone distribution, and expanding treatment for opioid use disorder was associated with an estimated 179 151 lives saved when compared with the status quo.

          Meaning

          The findings of this study suggest that the number of fatal opioid overdoses in the US is expected to remain high for at least 10 years, but evidence-based interventions may prevent a substantial fraction of these deaths.

          Abstract

          Importance

          The US opioid epidemic is complex and dynamic, yet relatively little is known regarding its likely future impact and the potential mitigating impact of interventions to address it.

          Objective

          To estimate the future burden of the opioid epidemic and the potential of interventions to address the burden.

          Design, Setting, and Participants

          A decision analytic dynamic Markov model was calibrated using 2010-2018 data from the National Survey on Drug Use and Health, Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey, the US Census, and National Epidemiologic Survey on Alcohol and Related Conditions–III. Data on individuals 12 years or older from the US general population or with prescription opioid medical use; prescription opioid nonmedical use; heroin use; prescription, heroin, or combined prescription and heroin opioid use disorder (OUD); 1 of 7 treatment categories; or nonfatal or fatal overdose were examined. The model was designed to project fatal opioid overdoses between 2020 and 2029.

          Exposures

          The model projected prescribing reductions (5% annually), naloxone distribution (assumed 5% reduction in case-fatality), and treatment expansion (assumed 35% increase in uptake annually for 4 years and 50% relapse reduction), with each compared vs status quo.

          Main Outcomes and Measures

          Projected 10-year overdose deaths and prevalence of OUD.

          Results

          Under status quo, 484 429 (95% confidence band, 390 543-576 631) individuals were projected to experience fatal opioid overdose between 2020 and 2029. Projected decreases in deaths were 0.3% with prescribing reductions, 15.4% with naloxone distribution, and 25.3% with treatment expansion; when combined, these interventions were associated with 179 151 fewer overdose deaths (37.0%) over 10 years. Interventions had a smaller association with the prevalence of OUD; for example, the combined intervention was estimated to reduce OUD prevalence by 27.5%, from 2.47 million in 2019 to 1.79 million in 2029. Model projections were most sensitive to assumptions regarding future rates of fatal and nonfatal overdose.

          Conclusions and Relevance

          The findings of this study suggest that the opioid epidemic is likely to continue to cause tens of thousands of deaths annually over the next decade. Aggressive deployment of evidence-based interventions may reduce deaths by at least a third but will likely have less impact for the number of people with OUD.

          Abstract

          This decision analytical model estimates the future burden of opioid-related morbidity and mortality in the US from 2020 to 2029 and examines strategies that may be associated with mitigation of the opioid epidemic.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

          Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction

            Annual Review of Public Health, 36(1), 559-574
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Relationship between Nonmedical Prescription-Opioid Use and Heroin Use

                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                4 November 2020
                November 2020
                4 November 2020
                : 3
                : 11
                : e2023677
                Affiliations
                [1 ]Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
                [2 ]Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
                [3 ]Monument Analytics, Baltimore, Maryland
                [4 ]The University of Chicago School of Social Service Administration, Chicago, Illinois
                [5 ]Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
                [6 ]Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland
                Author notes
                Article Information
                Accepted for Publication: August 31, 2020.
                Published: November 4, 2020. doi:10.1001/jamanetworkopen.2020.23677
                Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Ballreich J et al. JAMA Network Open.
                Corresponding Author: G. Caleb Alexander, MD, MS, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, W6035, Baltimore, MD 21205 ( galexan9@ 123456jhmi.edu ).
                Author Contributions: Dr Alexander had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Ballreich, Mansour, Pollack, Dowdy, Alexander.
                Acquisition, analysis, or interpretation of data: Ballreich, Mansour, Hu, Chingcuanco, Dowdy, Alexander.
                Drafting of the manuscript: Ballreich, Mansour, Hu, Pollack, Alexander.
                Critical revision of the manuscript for important intellectual content: Ballreich, Mansour, Chingcuanco, Pollack, Dowdy, Alexander.
                Statistical analysis: Ballreich, Mansour, Hu.
                Obtained funding: Alexander.
                Administrative, technical, or material support: Ballreich, Mansour, Hu, Chingcuanco, Pollack, Alexander.
                Supervision: Ballreich, Dowdy, Alexander.
                Conflict of Interest Disclosures: Dr Ballreich reported receiving consulting fees from Monument Analytics during the conduct of the study and is an employee of The Johns Hopkins University outside the submitted work. Mr Mansour and Ms Chingcuanco reported serving as paid employees of Monument Analytics. Ms Hu reported receiving consulting fees from Monument Analytics during the conduct of the study. Dr Pollack reported receiving consulting fees from Monument Analytics during the conduct of the study and is an employee of the University of Chicago outside the submitted work. Dr Dowdy reported receiving consulting fees from Monument Analytics during the conduct of the study and is an employee of The Johns Hopkins University outside the submitted work.
                Funding/Support: This development of the core model was funded in part by plaintiffs in opioid litigation as part of the Multidistrict Litigation (MDL 2804) in the Northern District of Ohio, United States District Court.
                Role of the Funder/Sponsor: Counsel reviewed the manuscript for confidential or privileged information but otherwise had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
                Additional Contributions: Brendan Saloner, PhD, and Joshua Sharfstein, MD (Johns Hopkins Bloomberg School of Public Health), provided feedback on specific model features and transition probabilities but were not financially remunerated for this feedback.
                Article
                zoi200785
                10.1001/jamanetworkopen.2020.23677
                7643029
                33146732
                4aac6b77-7aca-4008-89a3-c6bf59ecc988
                Copyright 2020 Ballreich J et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY-NC-ND License.

                History
                : 14 May 2020
                : 31 August 2020
                Categories
                Research
                Original Investigation
                Online Only
                Substance Use and Addiction

                Comments

                Comment on this article